NYU Langone Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).
NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.
NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,164 total, page 16 of 24
TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051
NCT02730403
Camp High 5: Evaluation of the Effect on Upper Limb Function
NCT02875054
Investigation of Human Laryngeal Evoked Brainstem Potentials
NCT02803359
PTNS Versus Sham Efficacy in Treatment of BPS
NCT02747420
Rehabilitation in the Home Setting for Older Adults In the Early Period After Myocardial Infarction
NCT02804906
The Effect of a Psychosensory Therapy
NCT02765932
Feasibility and Effectiveness of Colonic Irrigation
NCT02826967
Combining Restrictive Guidelines and a NIRS SCORE to Decrease RBC Transfusions
NCT02535208
A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 2
NCT02986841
A Natural History Study of Canavan Disease
NCT02851563
Genzyme Osteopenia/Osteoporosis Study
NCT02785744
The Physiological Effects of Pacing on Catheter Ablation Procedures to Treat Atrial Fibrillation
NCT02766712
TEE/Angio Fusion Study
NCT02737969
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
NCT02746705
NYULMC CareSmarts Pilot
NCT02726217
A Pilot Test of the Relaxation Response Resiliency Program (3RP) in Spanish Speaking World Trade Center Survivors With Post Traumatic Stress Disorder (PTSD)
NCT02723097
Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments
NCT02586896
Food as Medicine: An RCT to Study the Effect of Home Delivered, Medically Tailored Meals on Patients With Metastatic Cancer
NCT02887235
MMEPT for Traumatic Brain Injury
NCT02695043
Proactive Care Coordination for Cancer Survivors Who Smoke
NCT02723656
Helping Children With Trauma
NCT02737488
Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease
NCT02640339
A New Paradigm for Vitamin D Sufficiency
NCT02969850
Trial Comparing Microdebrider-Assisted Inferior Turbinoplasty (MAIT) vs Submucous Resection (SMR)
NCT02695602
Cognitive Detection of Preclinical AD: Validation Using Biomarkers
NCT02616679
Anxiety and COPD Evaluation
NCT02740465
Cardiopulmonary Outpatient Rehabilitation Using Mobile Technology
NCT02671669
Trial of Techniques for Umbilical Reconstruction
NCT02723409
Sputum-derived Cellular Targets After Xolair (Omalizumab)
NCT02658877
Mindfulness for Breast Cancer
NCT02647216
Healthy Families: Transforming Care for Obese Children at NYU Lutheran Family Health Centers
NCT02817009
Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes
NCT03020069
Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT
NCT02635035
Exercise and Transcranial Magnetic Stimulation: Increasing Brain Plasticity in Parkinson's Disease
NCT02741765
Sleep Health Education and Social Support Among Blacks With OSA
NCT02628977
Arsenic, Disordered Glucose Homeostasis and Atherosclerosis
NCT02759289
Sphenopalatine Ganglion Block to Treat Shoulder Pain During and/or After Cesarean
NCT02670057
Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer
NCT03656809
Overactive Bladder (OAB) Voiding Diary and Urodynamics Correlation Study
NCT03473782
Neurotrack Test Validation Protocol
NCT02608021
Brain Sleep Clearance of Amyloid-Beta Peptides
NCT02474251
Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention
NCT02347202
Diabetes CKD Lifestyle Technology Study
NCT02266823
Quantifying Quadriceps Atrophy Following Tibial Plateau Fracture
NCT02781623
Stress Response Pathways in Vitiligo
NCT02797574
CSII Pilot in Adolescents With Type 2 Diabetes
NCT02748122
Medications Effect on Lenstar Measurements
NCT02780063
Technical Development of up to 7T Magnetic Field Strength
NCT02666638
Visible Light Study
NCT02663921
Effects of Swaddling on Infants During Feeding
NCT02661360
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 99 |
| Phase 2 | 132 |
| Phase 3 | 28 |
| Phase 4 | 95 |
Therapeutic Areas
What is open in the NYU Langone Health pipeline
197 recruiting of 1,164 indexed (17% open); 741 completed (64%).
Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NYU Langone Health: open-pipeline peers nationwide
Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,164 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this NYU Langone Health page
1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.
- 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.